Abstract

The Varicella-zoster virus (VZV) or human herpes virus 3 is a neurotropic human alpha herpes virus responsible for chickenpox/varicella and shingles/Herpes zoster (HZ). This review will focus on HZ. Since HZ is secondary to varicella, its incidence increases with age. In children and youngsters, HZ is rare and associated to metabolic and neoplastic disorders. In adults, advanced age, distress, other infections (such as AIDS or COVID-19), and immunosuppression are the most common risk factors. HZ reactivation has recently been observed after COVID-19 vaccination. The disease shows different clinical stages of variable clinical manifestations. Some of the manifestations bear a higher risk of complications. Among the possible complications, postherpetic neuralgia, a chronic pain disease, is one of the most frequent. HZ vasculitis is associated with morbidity and mortality. Renal and gastrointestinal complications have been reported. The cornerstone of treatment is early intervention with acyclovir or brivudine. Second-line treatments are available. Pain management is essential. For (secondary) prophylaxis, currently two HZV vaccines are available for healthy older adults, a live attenuated VZV vaccine and a recombinant adjuvanted VZV glycoprotein E subunit vaccine. The latter allows vaccination also in severely immunosuppressed patients. This review focuses on manifestations of HZ and its management. Although several articles have been published on HZ, the literature continues to evolve, especially in regard to patients with comorbidities and immunocompromised patients. VZV reactivation has also emerged as an important point of discussion during the COVID-19 pandemic, especially after vaccination. The objective of this review is to discuss current updates related to clinical presentations, complications, and management of HZ.

Highlights

  • The Varicella-zoster virus (VZV) or human herpes virus 3 is the causative agent for both chickenpox/varicella and shingles/Herpes zoster (HZ)

  • HZ represents a reactivation of VZV in the host and has gained interest because of variable clinical presentation, which is important in the differential diagnosis of diseases

  • Two HZ vaccines are available for healthy older adults, a live attenuated VZV vaccine (Zostavax; Merck, Kenilworth, NJ, USA) and a recombinant adjuvanted VZV glycoprotein

Read more

Summary

Introduction

The Varicella-zoster virus (VZV) or human herpes virus 3 is the causative agent for both chickenpox/varicella and shingles/Herpes zoster (HZ). HZ represents a reactivation of VZV in the host and has gained interest because of variable clinical presentation, which is important in the differential diagnosis of diseases. HZ reactivation has been reported as a possible adverse event after COVID-19 vaccination. Treatment options and prevention by vaccination are of clinical importance. VZV reactivation has emerged as an important point of discussion during the COVID-19 pandemic, especially after vaccination. With this background, in this review we discuss the current updates related to clinical presentations, complications, and management of HZ. The literature was searched through PubMed and Google Scholar to retrieve relevant published articles on HZ. Herpes zoster” were used to search the articles. Articles published till 2021 along with reference lists of relevant articles were included for review

Etiology
Epidemiology
Clinical Stages
Special Clinical Patterns
Ramsay Hunt Syndrome
Deep HZ
Central Nervous System HZ
Postherpetic Neuralgia
Meningitis Retention Syndrome
Acute Colonic Pseudo-Obstruction
Keloids and Other Types of Isotopic Response
Pseudohernia Formation and Cysts
Erythema Multiforme
Vasculitis
Recurrent HZ
HZ and Occult Neoplasia
6.10. VZV Reactivation and COVID-19
Treatment with Biologicals
Medical Treatment
Vaccination
Findings
11. Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call